HepCBC Mission Statement

HepCBC is a non-profit organization run by and for people infected and affected by hepatitis C. Our mission is to provide education, prevention and support to those living with HCV.

The Best of the Week to You: June 9 - June 16, 2017

Hot Off The Press!

CHMP Backs Two Pan-Genotypic Antivirals for Hep C

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of two new drugs, Maviret and Vosevi, for the treatment of chronic hepatitis C virus (HCV) infection in adults. Maviret (AbbVie Ltd), administered once daily as three oral tablets, contains the NS3/4A protease inhibitor glecaprevir (100 mg) and the NS5A inhibitor pibrentasvir (40 mg). Vosevi (Gilead Sciences) is a once-daily single

New Zealand: Govt asked to greenlight prison Hep-C testing

The government is being asked to agree to a medical trial to find out how many prisoners have been exposed to Hepatitis C. An estimated 50,000 people in New Zealand have the disease, which is transmitted mainly through intravenous needles or badly sterilised medical equipment. Hepatitis C targets the liver, and can be fatal. Little is known about its prevalence in the prison population, but figures from other countries such as the USA and Ireland sugge

Burlington dental patients told to get tested for hepatitis and HIV

The Halton Regional Health Department in Ontario, Canada says 9,000 past and current patients of a Burlington dental clinic should get tested for infectious diseases. On June 9 the department identified that clients who received dental services at Upper Middle Dental operated by Dr. Vick Handa may have been exposed to improperly cleaned instruments used for procedures. “Improperly cleaned dental instruments carry a low risk of transmitting infectious d

Gilead Receives Approval in Canada for VEMLIDY™ (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

MISSISSAUGA, ON, June 19, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for VEMLIDY™ (tenofovir alafenamide, TAF) 25mg tablets, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease. – VEMLIDY is a Once-Daily Treatment that Demonstrated Similar Efficacy with Improved Renal and Bone Laboratory Safety Parameters C

The Week in Review: June 9 – June 16, 2017

Friday, June 16, 2017 News Recap Brenda’s Story Brenda and her husband were forced onto a journey they never wanted to take. Hepatitis C complications put her into a long coma and almost took her life. With luck, love, a generous stranger's liver, and a new hep C cure, she is not only alive but has returned to life with incredible strength and energy. She hopes her story will convince all baby boomers to get tested for hep C, for everyone who has he...